Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease

Not Applicable

Completed

• Conditions: Ischaemic heart disease (IHD); Circulatory System; Ischaemic heart disease

• Registration Number: ISRCTN32017426
• Lead Sponsor: The University of Dundee (UK)

Brief Summary

2016 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/27609859 protocol 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36216006/ (added 11/10/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38551218/ (added 03/04/2024)

Detailed Description

Not available

Study Timeline

• Study Start: 2013-08-16
• Study Completion: 2022-03-31
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 5937

Inclusion Criteria

1. Male or female patients aged 60 years and over
2. Ischaemic heart disease (IHD) defined as a diagnosis of angina or myocardial infarction (MI) at any time or other evidence ofischaemic heart disease (investigator opinion)

Exclusion Criteria

1. History of gout
2. Known severe renal impairment (eGFR <30ml/min)
3. Moderate to severe heart failure (NYHA III-IV)
4. Significant hepatic disease (eg ALT >3 x upper limit of normal, cirrhosis, ascites) (investigator opinion)
5. Patients currently taking part in another interventional clinical trial of an investigational medicinal product or medical device (or taken part in one within the last 3 months)
6. Previous allergy to allopurinol
7. Previous serious adverse cutaneous (skin) reaction to any drug (eg Stevens Johnson syndrome, toxic epidermal necrolysis, hospitalisation due to skin reaction to drug) (investigator opinion)
8. Patients already taking urate lowering therapy (including allopurinol, febuxostat, sulfinpyrazone, benzbromarone, probenecid, rasburicase)
9. Patients taking azathioprine, mercaptopurine, ciclosporin or theophylline
10. Malignancy (except non-metastatic, non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years (investigator opinion)

Study & Design

• Study Type: Interventional
• Study Design: Not specified